Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert(Institut Gustave Roussy), F. Stephen Hodi(Harvard University), Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), James R. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard W. Joseph(Daiichi Sankyo (United States)), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), Anthony M. Joshua(St Vincent's Hospital Sydney), Jin Zhang(Shanghai Jiao Tong University), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara C. Gangadhar(University of Pennsylvania), Adil Daud(University of California, San Francisco)
Cited by 485
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k